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Abstract: During menopause vasomotor symptoms are one of the main complaints about which 
women seek medical advice. For symptom control, several therapies have been used, among 
which hormone therapy has produced good results. One of these is estrogen monotherapy, which 
unfortunately may induce endometrial hyperplasia in women with an intact uterus. A progestin 
must be added to avoid this risk. Progestins may induce several secondary effects such as 
breast tenderness, hirsutism, edema and unfavorable lipid proﬁ  le modiﬁ  cations. Recently a 
new progestin called drospirenone has been synthesized and used in combination with estradiol 
for the treatment of postmenopausal women. This progestin is derived from spironolactone, 
and lacks estrogenic, androgenic and glucocorticoid activities. Several studies have evaluated 
safety, efﬁ  cacy and patient tolerability, and have shown a good proﬁ  le in all these parameters. 
All studies agree that the combination of estradiol 1 mg plus drospirenone 2 mg is a good choice 
for postmenopausal women with vasomotor symptoms.
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Introduction
Vasomotor symptoms are one of the main complaints in menopausal women, approximately 
85% of whom experience hot ﬂ  ushes, sweating, throbbing and chilling.1
Several treatments have been used to control these symptoms, but the most efﬁ  cient 
has proved to be hormone therapy (HT).2 This therapy also prevents genitourinary 
atrophy3 and osteoporosis development.4
Cardiovascular protection is a controversial theme with HT and current evidence 
indicates that early prescription, in the ﬁ  rst ﬁ  ve postmenopausal years, may induce 
cardiovascular protection.5
Estrogen therapy is the best choice for vasomotor symptoms control, but in women with 
an intact uterus, a progestin must be added to avoid the risk of endometrial hyperplasia or 
cancer.6 Estrogen plus progestin therapies have shown different results for lipid modiﬁ  ca-
tion, since these androgenic progestins have a deleterious effect on high density lipoprotein 
cholesterol; 7 also some progestins are associated with ﬂ  uid retention which can be associ-
ated with edema and breast tenderness and which may impair HT compliance.8
A new progestin, drospirenone (6β, 17β, 15β, 16β-dimethylen-3-oxo 1α-pregn-4-
ene-21, 17-carbo lactone), has a pharmacological proﬁ  le very similar to that of endog-
enous progesterone.9 It is derived not from testosterone but from 17α-spironolactone. It 
has progestational activity and lacks androgenic, estrogenic or glucocorticoid activities. 
Progestational activity is 4 times greater than that of progesterone.10,11
The renin-angiotensin-aldosterone system, by aldosterone action, prevents exces-
sive sodium loss, and promotes water retention with concomitant potassium and 
magnesium loss.9Clinical Interventions in Aging 2009:4 60
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In a rat model, drospirenone was shown to have 8 times 
the antialdosterone potency of spironolactone, and the antag-
onism exhibited by drospirenone is a result of its afﬁ  nity for 
the mineralocorticoid receptor.12 Sodium excretion increased 
from 79.6 to 98.6 mmol/day after drospirenone administra-
tion compared with placebo, in which no changes were 
observed.13 Because estrogen stimulates angiotensinogen 
synthesis,14 which promotes sodium and water retention, it 
can increase blood pressure, but progesterone prevents the 
interaction of aldosterone with mineralocorticoid receptors, 
which prevents this effect. Because drospirenone mimics the 
progesterone effect by the same mechanism it may be useful 
for hormone therapy.
Safety
Several studies have considered the safety of drospirenone 
use in addition to estradiol in postmenopausal women. One 
of the main goals of these studies has been endometrial safety 
as assessed by endometrial histology.
In one of these studies in which 1147 women were 
enrolled and randomized to receive either 1 mg estradiol 
alone or 1 mg estradiol in addition to 0.5, 1, 2 or 3 mg 
drospirenone, endometrial hyperplasia was found in 4.6% 
in the unopposed estradiol group, compared with 0.7% in 
patients receiving estradiol plus 2 mg drospirenone. No 
hyperplasia was reported in the groups receiving 0.5, 1 and 
3 mg drospirenone.15 Also endometrial thickness did not 
increase in the estradiol plus drospirenone group, while it 
was considerably increased by cycle 7 in the group receiving 
estradiol monotherapy.15
In another multicenter, double-blind, randomized, 
placebo-controlled study in which 225 healthy postmeno-
pausal women aged 45 to 65 years received 1 mg estradiol 
or 1, 2 or 3 mg drospirenone, it was found that endome-
trial thickness 5 mm was similar between baseline and 
ﬁ  nal examination. Three patients in each of the 1 mg and 
2 mg groups and the placebo group had an endometrial 
thickness 5 mm, 7 had no hyperplasia and 2 were not 
biopsied (1 in placebo and 1 in 1 mg group).16
In another study in which 1142 women between 42 and 
75 years age were randomized to receive drospirenone 0.5, 
1, 2 or 3 mg plus estradiol 1 mg or only 1 mg estradiol. The 
primary outcome variable was endometrial hyperplasia. 
A proliferative endometrium was found in 50.8% of those 
receiving estradiol monotherapy, while in those receiving 
drospirenone at doses of 0.5, 1, 2 or 3 mg it was found in 
16.2%, 13.0%, 8.2% and 6.2% respectively. Hyperplasia 
was diagnosed in 4% of those with estradiol monotherapy 
and 0.5% in the group receiving drospirenone 2 mg, with an 
0.007 probability of developing hyperplasia.17
In another study, in which 90 postmenopausal Korean 
women were randomized to receive estradiol 1 mg plus 
drospirenone 2 mg or placebo, a normal endometrium 
was found in the biopsies of 5 women with endometrial 
thickness 5 mm, 3 in the placebo and 2 in the estradiol 
plus drospirenone group.18
Cervical polyps were reported to occur with estradiol and 
drospirenone therapy, 2 in the 1 or 2 mg drospirenone group 
and 3 in the 3 mg drospirenone group.16 Also endometrial 
polyps were diagnosed in 3.1% receiving estradiol and 
drospirenone therapy compared with 3.0% receiving estradiol 
monotherapy.17
Lipid levels, blood pressure and coagulation factors have 
also been evaluated.
Lipids
When estradiol 1 mg alone or in combination with 0.5, 1, 2 or 
3 mg drospirenone was evaluated, cholesterol, triglycerides 
and low density lipoprotein levels were reduced with estradiol 
plus 0.5 or 2 mg drospirenone, but these changes were less 
marked with high density lipoprotein and lipoprotein (a).15 
In another study, mean total cholesterol values decreased in 
all estradiol plus drospirenone groups but not in the estradiol 
monotherapy group; also in this latter group triglyceride 
level increased. HDL-C increased more with drospirenone 
plus estradiol than with estradiol monotherapy. LDL-C 
decreased in all treatment groups. Signiﬁ  cant increases 
were found in HDL-C, HDL-C 3, apolipoprotein A1 and 
total phospholipids with estradiol monotherapy. Estradiol 
and drospirenone signiﬁ  cantly reduced total cholesterol and 
LDL-C, with a trend toward a decrease in triglycerides and 
total phospholipids and non-signiﬁ  cant increases in apoli-
poprotein A1, except for the 2 mg group and the estradiol 
monotherapy group. Larger decreases in apolipoprotein B 
were seen in estradiol drospirenone groups than in estradiol 
monotherapy groups.17
Blood pressure
In a multicenter study in which 225 healthy postmenopausal 
women aged 45 to 65 years received 1, 2 or 3 mg drospire-
none plus estradiol, a slight decrease in blood pressure was 
shown between the treatment groups which was slightly 
larger than in the placebo group.16
In another study in which estradiol 1 mg plus drospirenone 
0.5, 1, 2 or 3 mg were evaluated, blood pressure decreased in 
all treatment groups in a subgroup of hypertensive women, Clinical Interventions in Aging 2009:4 61
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but no differences were found in those with normal blood 
pressure. The decrease was greater with drospirenone than 
with estradiol monotherapy. The greatest decrease was 
observed in the 3 mg drospirenone group, and diastolic blood 
pressure signiﬁ  cantly decreased in the 0.5 and 2 mg groups.17 
In another study, 3 mg drospirenone dose also reduced blood 
pressure without changing potassium levels.19 Also, in a small 
study blood pressure tended to decrease in the estradiol 1 mg 
plus drospirenone 2 mg group.18 Most of the studies agree that 
2 mg drospirenone is the minimum effective dose that can 
achieve a blood pressure decrease.20,21
Coagulation
In a large study in which drospirenone 0.5, 1, 2 or 3 mg 
plus estradiol 1 mg or 1 mg estradiol alone were evaluated, 
ﬁ  brinogen levels decreased in the estradiol monotherapy 
group but not in the estradiol drospirenone group. Only the 
3 mg drospirenone group showed a decrease in plasminogen 
activator inhibitor antigen and no changes in potassium levels 
were found.17
In a study with 225 women, laboratory examinations 
found no changes between baseline and 16th week of treat-
ment in any of the estradiol and drospirenone groups.16
Efﬁ  cacy
Control of hot ﬂ  ushes is one of the most important parameters 
for assessing HT efﬁ  cacy, because they are one of the main 
reasons for women seeking medical advice.
When evaluating 1 mg estradiol alone or 1 mg estradiol 
plus 0.5, 1, 2 or 3 mg drospirenone, frequency and severity 
of hot ﬂ  ushes was reduced by week 2 in all treatment groups, 
with no differences between any of drospirenone doses.15
In another study in which 1 mg estradiol and 1, 2 or 
3 mg drospirenone were evaluated, the number of hot 
ﬂ  ushes decreased in all subjects by the 5th week of the 
study. A greater decrease was observed during treatment 
weeks 3 to 16 in active treatment groups than in the placebo 
group. The decrease between baseline and 16th week was 
greater in moderate and severe hot ﬂ  ushes than in mild ones 
(21.8–29.8 vs 1.0–2.0, 7.4–9.6 vs 1.4–3.7, respectively).16 
Another study reported that hot ﬂ  ushes began to decrease at 
week 2, with no differences between the groups.17
In a small study hot ﬂ  ushes decreased by 48.1% in the 
placebo group and by 84.4% in the estradiol 1 mg plus drospi-
renone 2 mg group. The decrease in the number of moderate 
and severe hot ﬂ  ushes was greater in the HT group as early 
as the ﬁ  rst month. Also the number of hot ﬂ  ushes decreased 
from an average of 27.8 to 31.5 at baseline to 5.8 to 8.6. 
The incidence of sweating episodes decreased 80% in the 
hormone group compared with 24% in the placebo. The 
incidence of insomnia decreased by 49% compared with 
14% in the placebo, and depression decreased from 31.4% 
to 14.3%, nervousness from 42.9% to 17.1% and vaginal 
dryness from 42.9% to 2.9%, respectively.18
Acceptability
The evaluation of spotting, breast pain and weight gain are 
important parameters for evaluating HT, since they will affect 
women’s long term continuation of treatment. Several studies 
have indicated that progestins such as medroxyprogesterone 
or norethindrone are less well tolerated because they have 
several adverse effects,22,23 which can be explained by their 
afﬁ  nities for the androgenic and glucocorticoid receptors.24
Spotting
In a large study in which several doses were evaluated, 
frequency of endometrial bleeding slightly increased after the 
ﬁ  rst cycle of treatment and decreased during the subsequent 
cycles, being 8% at 12 months in the estradiol and 2 mg 
drospirenone group.15
Also it has been observed that in drospirenone plus 
estradiol groups the mean bleeding days increased from 0 and 
0.2 in the ﬁ  rst treatment week to 1.6 to 2.2 at weeks 4 to 5. 
The number of bleeding days varied from 0.2 to 1.7 through 
the entire treatment period, with no difference between treat-
ment groups.16 This result agrees with that of another study in 
which a greater proportion of women in groups with estradiol 
plus drospirenone had bleeding in cycles 1 to 3 compared 
with those with estradiol monotherapy.17
It has also been reported that bleeding days decreased 
in the second half of the treatment. The maximum number 
of bleeding days was 1.8 at the sixth treatment week and 
decreased to 0.4 to 1.1 until the end of the study.18
Breast pain
Breast pain followed by headache were the main complaints 
reported by subjects in treated groups, while in the placebo 
group headache and abdominal pain were the main complaints: 
11 cases of breast pain were reported in the 1 mg drospire-
none group, 3 in the 2 mg drospirenone group, 2 in the 3 mg 
drospirenone group, and 1 in the placebo group. Permanent 
bleeding was reported in a woman in group 2 which was 
treated by hysterectomy, which revealed adenomiosis and 
several leiomyomata.16 Adverse effects were breast pain 
(experienced by 1.7%) and vaginal hemorrhage (1.6%). 
Of those on estradiol monotherapy, 19.6% reported breast Clinical Interventions in Aging 2009:4 62
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pain and 14.3% vaginal hemorrhage.17 In another study the 
most frequent adverse effect was breast pain followed by 
abdominal pain.18
Weight
Subjects receiving doses of 0.5 and 2 mg drospirenone plus 
estradiol maintained or even lost weight (0.4 and 0.8 kg 
respectively) compared with baseline.15
Another study, which evaluated 225 healthy postmeno-
pausal women, no changes were found in weight between 
the different drospirenone plus estradiol groups.16 However, 
in a large study a signiﬁ  cant decrease in mean body weight 
from baseline was observed at cycle 13 in the groups with 
2 and 3 mg drospirenone.17
Health-related quality of life
Mean scores on sf-36 for physical and mental health have 
been evaluated and were similar among the groups. Women’s 
health questionnaire showed an improvement in somatic 
symptoms by the end of cycle 13 in those groups receiving 
2 and 3 mg drospirenone in addition to estradiol compared 
with estradiol monotherapy. No differences in vasomotor 
symptoms were found between the groups. Psychological 
and somatic symptoms had a positive mean change but 
without statistical signiﬁ  cance.17 In the patient’s satisfaction 
questionnaire, all women in all treatment groups agreed that 
there were beneﬁ  ts with HT.17
Conclusion
Drospirenone 2 mg in addition to estradiol 1 mg is a good 
option for postmenopausal women, because of its proven 
efﬁ  cacy, safety and tolerability, and because it does not have 
the adverse effects of other progestins, owing to its lack of 
androgenic, estrogenic or glucocorticoid effect.
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